RxDoctor Payments Data

Andrew Wang, MD

Urology · Stockton, CANPI 1083146286

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,284 of the $1,908 with a category attached, or 67.3%. Boston Scientific accounts for 61.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $977 and has fallen 70.1% since, to $292 in 2025. That places this record below the midpoint for urology clinicians in CA, where the typical reported total is $2,485.

$1,908in general payments, 2019–2025

Across 27 payments — averaging $70.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • AbbVie$123
  • KARL Storz Endoscopy-america$95
  • Astellas Pharma US Inc$82
  • Procept Biorobotics Corporation$76
  • Dendreon Pharmaceuticals LLC$70
  • plus $289 from 6 others

What the payments were for

  • Travel & lodging$62333%
  • Food & beverage$1,28467%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,908 in reported general payments places this provider in the 45th percentile of 1,324 urology providers in California.

See all urology providers in California →

Medicare billing

Part B allowed, 2024
$279,512
Medicare patients
617
Services billed
3,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron33$20,975
GemtesaVibegron16$10,332
Testosterone39$6,862
Tamsulosin Hcl295$4,854
Oxybutynin Chloride ErOxybutynin Chloride88$2,775
Cefdinir117$1,755
Finasteride70$1,673
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$1,029
Terazosin Hcl17$853
Estradiol15$801
Alfuzosin Hcl ErAlfuzosin Hcl32$607
Dutasteride19$479
Oxybutynin Chloride35$344
Potassium Chloride16$338
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen72$332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$82$20,97533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,324 urology providers in California.

Other urology in Stockton

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →